कोशिश गोल्ड - मुक्त
Union Budget Drives Home.'VIKSIT BHARAT' MANTRA
Bio Spectrum
|August 2024
Presenting the Union Budget for the seventh time in a row on July 23, the Union Minister for Finance and Corporate Affairs, Nirmala Sitharaman proposed to abolish 'angel tax' for all classes of investors and announced several measures like operationalisation of the Anusandhan National Research Foundation (ANRF) for basic research and prototype development and setting up a mechanism for spurring private sector-driven research and innovation at commercial scale with a financing pool of Rs 1 lakh crore in line with the announcement in the interim budget.
The Budget has enhanced the allocation to the Department of Scientific and Industrial Research (DSIR) from Rs 5746.51 crore in 2023-24 to Rs 6323.41 crore 2024-25 marking an increase of 10.03 per cent, of which Rs 6265.80 crore has been earmarked for Council of Scientific & Industrial Research (CSIR).
The Union Budget 2024-25 is focussed on driving the growth and development of entrepreneurship, employment and skilling, making India a manufacturing hub of the world and boosting primary and secondary healthcare in the country factors by and large being hailed by leaders and experts as keystones on India's path of 'Viksit Bharat' to become one of the world's biggest economy. The Prime Minister asserted "Today's budget has brought new opportunities, new energy, new employment and self-employment opportunities. It has brought better growth and a bright future."
Healthcare/medtech
The government has increased the budget allocation for the healthcare sector by 15 per cent compared to the previous year. This increase aims to improve healthcare infrastructure and services across the country. Three cancer drugs namely Trastuzumab Deruxtecan, Osimertinib and Durvalumab have been fully exempted from custom duty, to make cancer treatment more affordable in the country. The budget has also introduced schemes to enable changes in Basic Customs Duty (BCD) on X-ray tubes & flat panel detectors for use in medical X-ray machines under the Phased Manufacturing Programme. Although the announcements have been welcomed by the healthcare sector, experts opine that customs duty reduction on finished goods is still a pending demand.
यह कहानी Bio Spectrum के August 2024 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Bio Spectrum से और कहानियाँ
Bio Spectrum
Syngene strengthens leadership team with 2 key appointments
Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), has announced the appointment of Maninder Kapoor Puri as Chief Human Resources Officer (CHRO) and Abhijit Zutshi as Chief Commercial Officer (CCO), effective May 1, 2026.
1 min
June 2026
Bio Spectrum
NIScPR signs MoU with RIS to strengthen science, technology, innovation, policy and diplomacy
To strengthen cooperation in the fields of science, technology, innovation, policy, and diplomacy, the National Institute of Science Communication and Policy Research (NISCPR) has signed a Memorandum of Understanding with the Research and Information System for Developing Countries (RIS).
1 min
June 2026
Bio Spectrum
Gaurav Jain steps into COO role at Redcliffe Labs
Redcliffe Labs has announced that Gaurav Jain has taken on the role of Chief Operating Officer (COO), marking a key leadership milestone as the company continues to scale its operations and strengthen its technology-led, consumer-first diagnostics ecosystem to make preventive diagnostics more accessible, affordable, accurate, and actionable across India.
1 min
June 2026
Bio Spectrum
ABEC expands Process Sciences Group to strengthen bioprocess optimisation capabilities
ABEC, a global leader in bioprocess engineering solutions, has announced the expansion of its Process Sciences group, expanding its ability to help biopharmaceutical manufacturers accelerate development, reduce risk, and improve productivity across the bioprocess lifecycle.
1 min
June 2026
Bio Spectrum
Amneal Pharma buys Kashiv BioSciences to create fully integrated global biosimilar leader
Kashiv BioSciences has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc.
1 min
June 2026
Bio Spectrum
Health Ministry unveils comprehensive guidance document on Diabetes Mellitus in children
In a historic step towards strengthening child health services, the Ministry of Health and Family Welfare has released the guidance document on Diabetes Mellitus in children.
1 min
June 2026
Bio Spectrum
“We want to develop mRNA vaccines for the most prevalent cancers in India”
A unique initiative of the Tata Trusts with a mission to support the application of cutting-edge science to solve societal problems, Bengaluru-based Tata Institute for Genetics and Society (TIGS) is deepening its efforts towards developing science-based solutions to prevent diseases and improve access to affordable and quality diagnostics and therapeutics in the country.
5 mins
June 2026
Bio Spectrum
Neuland secures development collaboration with LIR Life Sciences for transdermal GLP-1
Hyderabad-based Neuland Laboratories, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, has entered into a development partnership with LIR Life Sciences Corp, a Canada-based biotechnology company focused on scalable and accessible obesity treatments, in advancing its cell-penetrating peptide (CPP) platform.
1 min
June 2026
Bio Spectrum
IIT Madras announces $7.5 M Menlo Park deep-tech hub to drive Indian innovation into Silicon Valley
Indian Institute of Technology (IIT) Madras Global Research Foundation has announced the establishment of its first centre in the United States (US), located in Menlo Park, California, marking a significant milestone in expanding India's deep-tech innovation footprint into global ecosystems.
1 min
June 2026
Bio Spectrum
Oxford and Serum Institute of India to advance development of new malaria vaccine candidate
The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.
1 min
June 2026
Listen
Translate
Change font size
